Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade F 31.65 -4.32% -1.43
RGNX closed down 4.32 percent on Friday, August 14, 2020, on 1.24 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RGNX trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -4.32%
Oversold Stochastic Weakness -4.32%
Oversold Stochastic Weakness -2.74%
180 Bearish Setup Bearish Swing Setup -5.01%
Slingshot Bearish Bearish Swing Setup -5.01%
Oversold Stochastic Weakness -5.01%
Oversold Stochastic Weakness -6.64%
Oversold Stochastic Weakness -4.15%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Molecular Biology Gene Therapy Genetics Medical Genetics Applied Genetics Wet Age Related Macular Degeneration Gene Delivery Retinitis Pigmentosa Adeno Associated Virus Homozygous Familial Hypercholesterolemia Iduronidase X Linked Retinitis Pigmentosa

Is RGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.97
52 Week Low 20.03
Average Volume 345,882
200-Day Moving Average 39.06
50-Day Moving Average 36.35
20-Day Moving Average 34.78
10-Day Moving Average 33.41
Average True Range 1.78
ADX 25.73
+DI 11.94
-DI 26.23
Chandelier Exit (Long, 3 ATRs ) 34.65
Chandelier Exit (Short, 3 ATRs ) 36.73
Upper Bollinger Band 38.60
Lower Bollinger Band 30.96
Percent B (%b) 0.09
BandWidth 21.97
MACD Line -1.28
MACD Signal Line -1.07
MACD Histogram -0.2145
Fundamentals Value
Market Cap 977.79 Million
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -11.77
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.40
Resistance 3 (R3) 34.61 33.91 33.94
Resistance 2 (R2) 33.91 33.21 33.80 33.78
Resistance 1 (R1) 32.78 32.78 32.43 32.57 33.63
Pivot Point 32.08 32.08 31.91 31.97 32.08
Support 1 (S1) 30.95 31.38 30.60 30.74 29.67
Support 2 (S2) 30.25 30.95 30.14 29.52
Support 3 (S3) 29.12 30.25 29.36
Support 4 (S4) 28.91